FSGS
16
7
7
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
12.5%
2 terminated out of 16 trials
60.0%
-26.5% vs benchmark
25%
4 trials in Phase 3/4
133%
4 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (16)
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
Atacicept in Multiple Glomerular Diseases
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
NEPTUNE Match Study
A Study to Evaluate the Safety, Tolerability and PK of SK-09
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
A Study of CCX140-B in Subjects With FSGS
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
Bortezomib for Treating Glomerular Diseases
Acthar for Treatment of Post-transplant FSGS
Rituximab to Prevent Recurrence of Proteinuria
A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis